loading
Hepion Pharmaceuticals Inc stock is traded at $0.64, with a volume of 19,337. It is up +0.87% in the last 24 hours and down -1.54% over the past month. Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan-cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.
See More
Previous Close:
$0.6345
Open:
$0.6
24h Volume:
19,337
Relative Volume:
0.44
Market Cap:
$3.74M
Revenue:
-
Net Income/Loss:
$-44.68M
P/E Ratio:
-0.0535
EPS:
-11.96
Net Cash Flow:
$-36.70M
1W Performance:
-1.54%
1M Performance:
-1.54%
6M Performance:
-56.16%
1Y Performance:
-84.94%
1-Day Range:
Value
$0.60
$0.67
1-Week Range:
Value
$0.60
$0.68
52-Week Range:
Value
$0.5525
$4.47

Hepion Pharmaceuticals Inc Stock (HEPA) Company Profile

Name
Name
Hepion Pharmaceuticals Inc
Name
Phone
732-902-4000
Name
Address
399 THORNALL STREET, EDISON
Name
Employee
22
Name
Twitter
@HepionPharma
Name
Next Earnings Date
2024-11-18
Name
Latest SEC Filings
Name
HEPA's Discussions on Twitter

Hepion Pharmaceuticals Inc Stock (HEPA) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-20-20 Resumed ROTH Capital Buy

Hepion Pharmaceuticals Inc Stock (HEPA) Latest News

pulisher
Oct 26, 2024

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.67% - MSN

Oct 26, 2024
pulisher
Oct 15, 2024

Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Statistics, Drugs, Mechanism of Action, Route of Administration, and Companies by DelveInsight - The Globe and Mail

Oct 15, 2024
pulisher
Oct 04, 2024

Will Hepion's AMBITION Be Fulfilled? - RTTNews

Oct 04, 2024
pulisher
Sep 23, 2024

Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 4% - MarketBeat

Sep 23, 2024
pulisher
Sep 23, 2024

Hypha Labs, Inc. Releases Investor Presentation - AccessWire

Sep 23, 2024
pulisher
Sep 23, 2024

Does Hyliion Holdings Corporation (NYSE: HYLN) Still Need To Convince Analysts? - Stocks Register

Sep 23, 2024
pulisher
Sep 23, 2024

FluoRok raises US$ 9.8million for safety and sustainability of fluorochemical production - Indian Chemical News

Sep 23, 2024
pulisher
Sep 23, 2024

FLO stock rated an Underperform by Exane BNP Paribas - Knox Daily

Sep 23, 2024
pulisher
Sep 23, 2024

Barrow Hanley Mewhinney & Strauss LLC Purchases Shares of 898,419 Helios Technologies, Inc. (NASDAQ:HLIO) - MarketBeat

Sep 23, 2024
pulisher
Sep 23, 2024

Hancock Whitney Corp Buys 10,920 Shares of PHINIA Inc. (NYSE:PHIN) - MarketBeat

Sep 23, 2024
pulisher
Sep 23, 2024

FluoRok Raises £7.7M in Funding - FinSMEs

Sep 23, 2024
pulisher
Sep 23, 2024

Oxford's FluoRok secures €9.2M from BGF and others - Silicon Canals

Sep 23, 2024
pulisher
Sep 23, 2024

HilleVax, Inc. (NASDAQ:HLVX) Given Consensus Rating of “Hold” by Analysts - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

PHINIA Inc. (NYSE:PHIN) Shares Acquired by Long Road Investment Counsel LLC - Defense World

Sep 23, 2024
pulisher
Sep 22, 2024

King Luther Capital Management Corp Boosts Position in Helios Technologies, Inc. (NASDAQ:HLIO) - Defense World

Sep 22, 2024
pulisher
Sep 19, 2024

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) Short Interest Update - Defense World

Sep 19, 2024
pulisher
Sep 06, 2024

Hepion Pharmaceuticals faces Nasdaq delisting over share price - Investing.com

Sep 06, 2024
pulisher
Sep 04, 2024

Pharma Two B and Hepion Pharmaceuticals file for merger - Investing.com

Sep 04, 2024
pulisher
Sep 04, 2024

Pharma Two B and Hepion Pharmaceuticals file for merger By Investing.com - Investing.com UK

Sep 04, 2024
pulisher
Sep 04, 2024

Hepion, Pharma Two B file registration statement for proposed merger - TipRanks

Sep 04, 2024
pulisher
Sep 04, 2024

Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger - ForexTV.com

Sep 04, 2024
pulisher
Sep 03, 2024

Hepion Pharmaceuticals (NASDAQ:HEPA) Trading 4.7% Higher - Defense World

Sep 03, 2024
pulisher
Aug 30, 2024

TNF Pharmaceuticals (NASDAQ:TNFA) Stock Quotes, Forecast and News Summary - Benzinga

Aug 30, 2024
pulisher
Aug 21, 2024

HEPA Stock Earnings: Hepion Pharmaceuticals Reported Results for Q2 2024 - MSN

Aug 21, 2024
pulisher
Aug 19, 2024

HEPION PHARMACEUTICALS INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com

Aug 19, 2024
pulisher
Aug 13, 2024

GSK, Novartis lead July deals as biopharma sector sees more than $20B for the month - BioWorld Online

Aug 13, 2024
pulisher
Aug 07, 2024

Hepion Pharmaceuticals announces executive leadership changes - Investing.com India

Aug 07, 2024
pulisher
Aug 07, 2024

Hepion Pharmaceuticals announces executive leadership changes By Investing.com - Investing.com UK

Aug 07, 2024
pulisher
Aug 01, 2024

Following restructuring, Hepion to merge with Israeli pharma firm - NJBIZ

Aug 01, 2024
pulisher
Jul 26, 2024

Cingulate (NASDAQ:CING) Stock Quotes, Forecast and News Summary - Benzinga

Jul 26, 2024
pulisher
Jul 24, 2024

HEPA hits 52-week low, trading at 0.7324 USD - Investing.com

Jul 24, 2024
pulisher
Jul 24, 2024

HEPA hits 52-week low, trading at 0.7324 USD By Investing.com - Investing.com Canada

Jul 24, 2024
pulisher
Jul 24, 2024

Oligonucleotide Therapy Market Targeting the Future of Medicine: Oligonucleotide Therapies Offer Precision ... - WhaTech

Jul 24, 2024
pulisher
Jul 23, 2024

Financial Health Check: Examining Hepion Pharmaceuticals Inc (HEPA)’s Key Ratios - The Dwinnex

Jul 23, 2024
pulisher
Jul 23, 2024

Aurora Innovation Inc [AUR] Is Currently -0.71 below its 200 Period Moving Avg: What Does This Mean? - The DBT News

Jul 23, 2024
pulisher
Jul 22, 2024

Oligonucleotide Therapy Market to Reach USD 19.92 Billion by 2031 | InsightAce Analytic - openPR

Jul 22, 2024
pulisher
Jul 22, 2024

The Globe and Mail - The Globe and Mail

Jul 22, 2024
pulisher
Jul 22, 2024

Oligonucleotide Therapy Market Transforming Healthcare: - openPR

Jul 22, 2024
pulisher
Jul 22, 2024

Hepion Pharmaceuticals Inc’s Banking’s 100-Day Moving Average at 1.6118: Will the Stock Break Through? - The InvestChronicle

Jul 22, 2024
pulisher
Jul 22, 2024

The Hepion Pharmaceuticals Inc (HEPA) Stock Is Headed for a Correction - US Post News

Jul 22, 2024
pulisher
Jul 22, 2024

IQVIA 'Is A Solid Investment' With Strong Competitive Positioning, Analyst Says After Better Than Expected Q2 Earnings - Markets Insider

Jul 22, 2024
pulisher
Jul 22, 2024

Fatty-Liver Focused Hepion Pharmaceuticals Agrees To Merge With Israel-Based Parkinson's Disease Drug Developer - Benzinga

Jul 22, 2024
pulisher
Jul 22, 2024

Hepion Pharmaceuticals’ Strategic Merger and Corporate Restructuring - TipRanks

Jul 22, 2024
pulisher
Jul 22, 2024

Pharma Two B Announces Plans to Go Public via Merger with Hepion Pharmaceuticals, Inc. and Concurrent $11.5 Million Private Placement - StockTitan

Jul 22, 2024
pulisher
Jul 18, 2024

Hepion Pharmaceuticals (NASDAQ:HEPA) Stock Quotes, Forecast and News Summary - Benzinga

Jul 18, 2024
pulisher
Jul 13, 2024

Biogen Inc. to Post Q2 2024 Earnings of $4.12 Per Share, Leerink Partnrs Forecasts (NASDAQ:BIIB) - American Banking and Market News

Jul 13, 2024
pulisher
Jul 13, 2024

Short Interest in Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) Grows By 58.4% - Defense World

Jul 13, 2024
pulisher
Jul 13, 2024

Glencore (OTCMKTS:GLNCY) Stock Price Passes Above Two Hundred Day Moving Average of $11.24 - American Banking and Market News

Jul 13, 2024
pulisher
Jul 11, 2024

SEC Form S-1 filed by Hepion Pharmaceuticals Inc. - Quantisnow

Jul 11, 2024
pulisher
Jul 03, 2024

BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Up 6.5% - Defense World

Jul 03, 2024
pulisher
Jun 28, 2024

Non-alcoholic Steatohepatitis (MASH) Treatment Market - openPR

Jun 28, 2024

Hepion Pharmaceuticals Inc Stock (HEPA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.30
price up icon 1.75%
$75.59
price down icon 0.20%
$374.10
price down icon 0.29%
$52.67
price down icon 0.85%
$207.67
price up icon 0.20%
$108.59
price up icon 0.02%
Cap:     |  Volume (24h):